Knopp Biosciences LLC Provides Update on Areteia Therapeutics Dexpramipexole Program

PITTSBURGH, PA, FEBRUARY 13, 2024 – Knopp Biosciences LLC reported today that Areteia Therapeutics Inc. announced the completion of a $75 million expansion of its Series A funding. The additional funds will be used to expand three ongoing Phase III clinical trials for dexpramipexole in the treatment of eosinophilic asthma. The financing was led by Bain Capital Life Sciences. Additional information regarding the transaction is available at https://www.businesswire.com/news/home/20240213672000/en/Areteia-Therapeutics-Announces-Additional-75MM-in-Series-A-Financing-for-Oral-Dexpramipexole-in-Eosinophilic-Asthma. About Knopp Biosciences LLC Knopp Biosciences LLC is a privately held, Pittsburgh-based holding company managing a portfolio of contractual payments and equity interest related to the sale of its Kv7 and dexpramipexole platforms. Please visit www.knoppbio.com.

The release as fetched from its publisher. knoppbio.com ↗